A share price of Cellectar Biosciences Inc [CLRB] is currently trading at $0.26, up 7.40%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CLRB shares have gain 6.02% over the last week, with a monthly amount drifted -9.28%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ROTH Capital started tracking the stock assigning a Buy rating. Ladenburg Thalmann initiated its recommendation with a Buy and recommended $2.70 as its price target on December 21, 2016.
Cellectar Biosciences Inc experienced fluctuations in its stock price throughout the past year between $0.22 and $3.42. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Cellectar Biosciences Inc [NASDAQ: CLRB] shares were valued at $0.26 at the most recent close of the market. An investor can expect a potential return of 4515.38% based on the average CLRB price forecast.
Analyzing the CLRB fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -1.96 and Total Capital is -4.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2501 points at the first support level, and at 0.2361 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2725, and for the 2nd resistance point, it is at 0.2809.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cellectar Biosciences Inc [NASDAQ:CLRB] is 2.47. Further, the Quick Ratio stands at 2.47, while the Cash Ratio is 2.31.
Transactions by insiders
Recent insider trading involved Longcor Jarrod, Chief Operating Officer, that happened on Jan 10 ’25 when 30000.0 shares were purchased.
